BIOPEPTIDES CORP
Ridgefield, CT · Medtech · Private
Multiplex paper-based point-of-care diagnostic assay for Lyme disease using B. burgdorferi-specific peptide antigens and smartphone-based reader
- Grants
- $12M
- 18 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 2 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of an Antigen Capture Assay for Babesia microti | $286,079 | |
| Federal grant | Department of Health and Human Services · Phase I · Peptide-based Multiplex Assay for Lyme disease Serodiagnosis | $176,282 | |
| Federal grant | Department of Health and Human Services · Phase I · Peptide-based Multiplex Assay for Lyme disease Serodiagnosis | $176,282 | |
| Federal grant | Department of Health and Human Services · Phase I · A Rapid Point-of-Care Assay for the Diagnosis of Lyme Disease | $151,776 | |
| Federal grant | Department of Health and Human Services · Phase I · A Rapid Point-of-Care Assay for the Diagnosis of Lyme Disease | $151,776 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a cytokine release assay for the diagnosis of Lyme disease | $605,367 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a cytokine release assay for the diagnosis of Lyme disease | $605,367 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · An antigen-capture assay to screen donated blood for Babesia microti | $299,812 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · An antigen-capture assay to screen donated blood for Babesia microti | $599,624 | |
| Federal grant | Department of Health and Human Services · Phase I · An antigen-capture assay to screen donated blood for Babesia microti | $299,812 | |
| Federal grant | Department of Health and Human Services · Phase II · A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease | $300,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease | $1,000,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease | $3,023,104 | |
| Federal grant | Department of Health and Human Services · Phase II · A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease | $986,480 | |
| Federal grant | Department of Health and Human Services · Phase II · A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease | $65,384 | |
| Federal grant | Department of Health and Human Services · Phase II · A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease | $971,240 | |
| Federal grant | Department of Health and Human Services · Phase II · A point of care vertical flow assay for the direct detection of Babesia microti and the serodiagnosis of Lyme disease. | $971,664 | |
| Federal grant | Department of Health and Human Services · Phase II · A point of care vertical flow assay for the direct detection of Babesia microti and the serodiagnosis of Lyme disease. | $962,204 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2065 | Bionic Eye Technologies, Inc. | — | — |
| 2066 | OPTOSURGICAL LLC | — | — |
| 2067 | ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC | — | — |
| 2068 | BIOPEPTIDES CORP | — | — |
| 2069 | E-Lambda LLC | — | — |
| 2070 | 21MedTech LLC | — | — |
| 2071 | VIZMA LIFE SCIENCES INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Peptides For Diagnosing Lyme Diseasegranted
- Diagnostic Peptides For Lyme Diseasegranted
- Compositions And Methods For Diagnosing Lyme Disease And For Predicting Lyme Disease Spirochete Elimination After Treatmentapplication
- Peptides For Diagnosing Lyme Diseaseapplication
- Peptides For Diagnosing Lyme Disease - 1application
- Diagnostic Peptides For Lyme Diseaseapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.